The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD

计划入组 30 人 · 首次发布于 2005 年 9 月 13 日

The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease

计划入组 12 人 · 首次发布于 2005 年 9 月 13 日

A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke

计划入组 300 人 · 首次发布于 2003 年 11 月 24 日

CP-101616

CP-1050

CP-506

CP SKIN HEALTH GROUP, INC.

United States

CP AUSTRALIA WELLCO PTY LTD

Australia

河南金康药业有限公司

Novel NMDA Receptor Modulator Onfasprodil Shows Rapid Antidepressant Effects with Reduced Side Effects in Phase 2 Trial

Olverembatinib Shows Promise as Second-Line Therapy for Chronic Phase CML

Merlin CP-GEP Test Shows Breakthrough Results in Melanoma Risk Assessment and Treatment Planning